title: Angioinvasive aspergillosis presenting as neutropenic colitis.
authors.forename: S
authors.initials: S
authors.lastname: Finn
authors.forename: J
authors.initials: J
authors.lastname: Bond
authors.forename: D
authors.initials: D
authors.lastname: McCarthy
authors.forename: K
authors.initials: K
authors.lastname: Sheahan
authors.forename: C
authors.initials: C
authors.lastname: Quinn
mesh_terms: D000068879:Adalimumab; D000276:Adjuvants, Immunologic / Q000009:adverse effects; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000276:immunology* / Q000473:pathology*; D002763:Cholecystectomy; D003092:Colitis / Q000473:pathology*; D003106:Colon / Q000098:blood supply; D003937:Diagnosis, Differential; D005260:Female; D046449:Hernia, Abdominal / Q000473:pathology; D006801:Humans; D016867:Immunocompromised Host; D007555:Isoxazoles / Q000009:adverse effects; D000077339:Leflunomide; D010198:Pancytopenia / Q000139:chemically induced; D012216:Rheumatic Diseases / Q000188:drug therapy
chemical_list: D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007555:Isoxazoles; D000068879:Adalimumab; D000077339:Leflunomide